Quarterly report pursuant to Section 13 or 15(d)

NON CONTROLLING INTEREST (Details)

v3.22.2.2
NON CONTROLLING INTEREST (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Net loss attributable to the non-controlling interest     $ (4,195) $ (1,866)
BioCorRx Pharmaceuticals, Inc [Member]        
Net loss $ (7,802) $ (1,643) $ (17,335) $ (7,709)
Average Non-controlling interest percentage of profit/losses 24.20% 24.20% 24.20% 24.20%
Net loss attributable to the non-controlling interest $ (1,888) $ (398) $ (4,195) $ (1,866)